Table 1.

Clinical inputs and utilities

Parameter		Value	95 % LCI/ minimum value	95 % UCI/ maximum value	Reference
Response rate—8 week	Adalimumab/standard care (RR)	1.34	1.02	1.77	[6]
	Standard care alone	0.25	0.20	0.31	[6]
Remission rate—8 week	Adalimumab/standard care (RR)	1.77	1.10	2.86	[6]
	Standard care alone	0.09	0.06	0.13	[6]
The probability of response per cycle—52 week	Standard care alone	0.016	0.010	0.023	[6]
Response per cycle—52 week (RR)	Adalimumab/standard care	1.32	0.80	2.18	[6]
The probability of remission per cycle—52 week	Standard care alone	0.014	0.009	0.020	[6]
Remission per cycle—52 week (RR)	Adalimumab/standard care	2.03	1.24	3.32	[6]
The probability of response loss per cycle—8–52 weeks	Adalimumab/standard care	0.161	–	–	[6]
	Standard care alone	0.158	–	–	[6]
The probability of remission loss per cycle—8–52 weeks	Adalimumab/standard care	0.000	–	–	[6]
	Standard care alone	0.016	–	–	[6]
The probability of complications after surgery		0.53	0.27	0.53	[11]
Surgery rate per cycle	Adalimumab/standard care (RR)	0.77	0.33	1.86	[10]
	Standard care alone	0.75 %	–	–	[10]
Utilities	Active treatment	0.420	0.320	–	[12, 13]
	Remission	0.880	0.790	0.910	12, 13]
	Response	0.760	0.580	0.940	[12]
	Remission after surgery	0.610	–	–	[12]
	Complications after surgery	0.420	–	0.490	[12, 13]

RR relative risk, LCI lower confidence interval, UCI upper confidence interval